Novartis’ Lutathera is now the first radiopharmaceutical approved for adolescents with a rare cancer found in the gut. The ...

The FDA granted accelerated approval to Day One Biopharmaceuticals' pediatric brain tumor treatment. The regulator on Tuesday ...

Stephanie DeViteri is taking over as Inizio Evoke Comms’ president for North America, returning to the agency where she spent ...

Tessera Therapeutics, Flagship’s major bet on what it calls gene writing, is letting go 13% to 14% of its workforce, a ...

China’s GNI Group announced on April 18 that it has signed an agreement with Chinese state-owned enterprises and ...

Pfizer and Novo Nordisk are both set to take the main stages at Cannes' advertising confab this summer. The just-announced ...

Novartis appears headed in the right direction now that Sandoz has been spun out, operations have been streamlined and the ...

In the 37 years since co-founding ARCH Venture Partners, Bob Nelsen has built a reputation for placing head-turning bets on ...

Endpoints News reported that former Stanford president Marc Tessier-Lavigne will lead one of biotech’s biggest-ever startup ...

To help meet the heightened demand for its injectable products, Eli Lilly is acquiring a facility from Nexus Pharmaceuticals, ...

Incyte said it will pay $750 million to buy San Diego biotech Escient Pharmaceuticals and its pipeline of early-stage drug ...

Headspace, best known for its app that guides people through meditation, now wants to help more of its customers get mental ...